Navigation Links
Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis
Date:3/26/2008

st physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

"Safe Harbor" Statement Under The Private Securities Litigation Reform Act of 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research, product development including, but not limited to the successful development of JUVISTA(R) (Human TGFbeta3) and veleglucerase alfa (GA-GCB); manufacturing and commercialisation including, but not limited to, the establishment in the market of YVANSE(TM) (lisdexamfetamine dimesylate) (Attention Deficit and Hyperactivity Disorder ("ADHD")); the impact of competitive products, including, but not limited to, the impact of those on Shire's ADHD franchise; patents, including but not limited to, legal challenges relating to Shire's ADHD franchise; government regulation and approval, including but not limited to the expected product approval date of INTUNIV(TM) (guanfacine ex
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
10. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
11. Shire Engages Palio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... diseases that afflict skeletal growth through abnormalities in ... fetal stage and is caused by genetic mutations. ... factor receptor 3 (FGFR3) has been associated with ... a skeletal dysplasia that cause serious respiratory problems ... (ACH), which causes stunted growth and other complications ...
(Date:9/18/2014)... Scientists at USC have developed a new microscopy ... in living animals at higher-than-ever resolution. , Dubbed ... allows imaging resolutions that are an order of ... insights into the behavior of biomolecules at the ... Sept. 18 by Nature Communications , the ...
(Date:9/18/2014)... Silicon-valley Electronic Data Capture (EDC) provider ... , the latest addition to Clinovo’s CRO Partnership Program. ... (CRO) Program, Clinovo further expands its global reach to ... training, we are now able to build studies on ... can also rely on Clinovo to fully support the ...
(Date:9/18/2014)... Whitehouse Laboratories is pleased to announce that ... has acquired an additional 4,000 square feet of dedicated ... adjacent to its current package testing facility. The official ... Whitehouse Labs is in the process of upgrading the ... testing. The prime location enables Whitehouse Labs to immediately ...
Breaking Biology Technology:Researchers use iPS cells to show statin effects on diseased bone 2Researchers use iPS cells to show statin effects on diseased bone 3Scientists pioneer microscopy technique that yields fresh data on muscular dystrophy 2Digitaliza TXT Joins Clinovo’s CRO Partnership Program, Bringing Its Open Source EDC System, ClinCapture to Latin America 2Digitaliza TXT Joins Clinovo’s CRO Partnership Program, Bringing Its Open Source EDC System, ClinCapture to Latin America 3Whitehouse Labs Announces Package Testing Laboratory Expansion 2Whitehouse Labs Announces Package Testing Laboratory Expansion 3Whitehouse Labs Announces Package Testing Laboratory Expansion 4
... of Pittsburgh School of Dental Medicine are piecing together ... to novel nanoscale approaches to developing biomaterials. The findings ... of the National Academy of Sciences . Dental ... and combines high hardness with resilience, said Elia Beniash, ...
... NeoStem, Inc. (NYSE Amex: NBS ) ("NeoStem" ... focus on cell based therapeutics development, today announced that ... Program (PRMRP) of the Office of the Congressionally Directed ... be applied towards funding the Company,s VSEL™ Technology. This ...
... testing within the pharmaceutical and cosmetic industries and companies ... their products are safe to use. Research published in ... demonstrates that the response of laboratory grown human cells ... or non-sensitizing, and can even predict the strength of ...
Cached Biology Technology:NeoStem Announces the Receipt of Over $1,700,000 in DOD Funding for its VSEL™ Technology Being Developed to Treat Osteoporosis 2NeoStem Announces the Receipt of Over $1,700,000 in DOD Funding for its VSEL™ Technology Being Developed to Treat Osteoporosis 3NeoStem Announces the Receipt of Over $1,700,000 in DOD Funding for its VSEL™ Technology Being Developed to Treat Osteoporosis 4Cell-based alternative to animal testing 2
(Date:9/17/2014)... New research from the Copenhagen Centre for Social Evolution ... evolutionary theory that birth weight and -length can partially ... disorders such as autism and schizophrenia later in life. ... births, and subsequent hospital diagnoses for up to 30 ... factors. The study is published today in the ...
(Date:9/17/2014)... obtained the first partial genome sequence of an ancient ... the site of the Montsoriu Castle in Girona, the ... related to today,s Iberian pig. Researchers also discard the ... pigs. , The study, published in Heredity , ... and particularly on that of the Iberian breed, considered ...
(Date:9/17/2014)... retinoblastoma protein gene are a leading cause of eye ... fruit fly eyes to unlock the secrets of this ... on the cover of the current issue of the ... researchers provide the first detailed examination of a set ... cancer gene, said Irina Pushel, MSU undergraduate and co-author. ...
Breaking Biology News(10 mins):Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3Iberian pig genome remains unchanged after 5 centuries 2Abnormal properties of cancer protein revealed in fly eyes 2
... North Grafton, Mass., August 10, 2011 Second graders ... to maintain their reading skills during the dog days of ... Cummings School of Veterinary Medicine at Tufts University. In ... second-grade students with a range of reading aptitudes and attitudes ...
... structure of a complex formed when a protein binds ... how an antibiotic-producing organism controls resistance to its own ... antibiotic producers regulate export to prevent self-toxicity. , The ... complex and highly regulated process, not least because the ...
... , Invasive species cost an estimated $1.4 trillion annually ... second only to habitat loss as a threat to ... invasive species, the question of why some species are ... Dr. Alison Bennett and Dr. Sharon Strauss at the ...
Cached Biology News:Days spent reading to dogs during summer may help avoid decline of reading skills 2Student brings home new expertise to answer question in antibiotic resistance 2Student brings home new expertise to answer question in antibiotic resistance 3Waging war on invasive plant species: Effects of invasives persist even after removal 2
Rabbit polyclonal antibody to NMDA NR2B [Tyr1336]...
... DeCypher combines enterprise-scale sequence analysis software with the ... analyses. With DeCypher, you can perform searches like ... vs NCBI NT database in under 6 days ... genomic DNA Use HMM analysis to ...
... Reagent A: MTT, (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide), 50mg/vial. ... is cleaved by living cells to yield ... requires active mitochondria, and even freshly dead ... MTT. Reagent A is a component of ...
Mouse monoclonal antibody to FMN2 - formin 2...
Biology Products: